Posts

Sweden gets into the Article 3 SPC referral game in AstraZeneca dapagliflozin case

New SPC referral to the CJEU on the interpretation of Art 3(a) and (c) for combination products (Merck v Clonmel)

The SPC alphabet: Are combination product SPCs precluded by Article 3(a), (c) and/or (d)?

Intellectual Property Challenges in the Bio-Pharmaceutical Field